Comparative Epidemiological Profiles in Prostate Cancer Algerian and Mauritanian Patients: Retrospective Study of 124 Case

• Abdelkrim Berroukche

  Research Laboratory of Water Resources and Environment, Biology Department, Faculty of Science, Dr Tahar-Moulay University, Saida 20000, Algeria

• Ely Mohamed-Amine

  National Oncology Center and Friendship Hospital, Nouakchot, Mauritania

• Mohamed Terras

  Research Laboratory of Water Resources and Environment, Biology Department, Faculty of Science, Dr Tahar-Moulay University, Saida 20000, Algeria

• Miloud Slimani

  Laboratory of Bio Toxicology, Pharmacognosy and Biological recycling plant, Biology Department, Faculty of Science, Dr Tahar-Moulay University, Saida 20000, Algeria

Prostate cancer (Pca) is a common neoplasia in elderly men. Its incidence increased over the last two decades in the Northern Africa. This study aimed to perform a comparison between epidemiological profiles of Pca in patients from two Maghreb countries (Algeria and Mauritania). This is a retrospective study carried out during 2014-2016, on population of 124 cases including 64 Pca Algerian patients recorded in the Oncology Department of Saida hospital, the Urology Department of Oran University Hospital and 60 Pca Mauritanians patients recruited in the National Oncology Center and the Friendship Hospital in Nouakchott. For these Pca patiens of different ethnic origin, demographic characteristics were studied and biological monitoring of the tumor marker PSA (prostate specific antigen) was performed in medical biological analysis laboratories using the same methods of serum-PSA assay. The mean age was significantly different in both groups of Pca Algerian and Mauritanian patients (respectively 74 vs 70 years). No significant positive correlation between the age and the PSA, in both groups, was recorded (R = 0.00796 vs R = 0.127) (p ˃ 0.05). The mean serum- PSA levels were 156.5 ± 76.4 ( Pca Algerians) and 179.3 ± 52.1 ng / mL (Pca Mauritanians). Histological evidence was obtained in 54.6 % (Pca Algerians) and 23.3 % (Pca Mauritanian patients). 15 Pca Patients with metastatic tumor stage and 17 cases of death were found. Prostate cancer essentially affects men old over 50 years in both Northern African countries and this comparative study showed the same methods of screening, diagnosis and therapeutic treatment of Pca used in these two areas.

Boyle P, Severi G, Giles GG. The epidemiology of prostate cancer. Urol Clin North Am 2003; 30: 209-17. https://doi.org/10.1016/S0094-0143(02)00181-7

World Health Organisation (WHO). Cancer report. 2012.

http://globocan.iarc.fr/Pages/fact_sheets_population.aspx

Fournier G, Valeri A, Mangin P, Cussenot O. Prostate cancer, epidemiology, risk factors and pathology. Annales d’Urologie 2004; 38: 187-206. https://doi.org/10.1016/j.anuro.2004.07.001

Zhang J, Wang L, Zhang Y, Li L, Higgins L, Lü J. Lobe-specific proteome changes in the dorsal-lateral and ventral prostate of TRAMP mice versus wild-type mice. Proteomics 2011; 11(12): 2542-49. https://doi.org/10.1002/pmic.201100008

Quinn M and Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. II. Individual countries. BJU Int 2002; 90: 174-84. https://doi.org/10.1046/j.1464-410X.2002.02823.x

Ravery V, Dominique S, Hupertan V, Ben Rhouma S, Toublanc M, Boccon-Gibod L, et al. Prostate Cancer Characteristics in a Multiracial Community. European Urology 2008; 53: 533-39. https://doi.org/10.1016/j.eururo.2007.04.048

Ndoye M, Niang L, Gandaho KI, Jalloh M, Labou I, Gueye S. Cancer avancé de la prostate au Sénégal. Aspects diagnostiques à l’hôpital de Grand Yoff. Progrès en Urologie 2014; 24: 271-75. https://doi.org/10.1016/j.purol.2013.08.317

Shibata A, Whittemore AS. Genetic predisposition to prostate cancer: possible explanations for ethnic differences in risk. Prostate 1997; 32: 65-72. https://doi.org/10.1002/(SICI)1097-0045(19970615)32:1<65::AID-PROS9>3.0.CO;2-B

Dieye M, Veronique-Baudin J, Draganescu C, Azaloux H. Cancer incidence in Martinique: a model of epidemiological transition. Eur J Cancer Prev 2007; 16: 95-101. https://doi.org/10.1097/01.cej.0000236246.78736.51

Amégbor K, Yao Seddoh T, Tengué K, Songne-Gnamkoulamba B, Napo-Koura G, James K. Épidémiologie et histopronostic du cancer de la prostate au Togo : à propos de 202 cas diagnostiqués au laboratoire d’anatomie pathologique du CHU Tokoin de Lomé. Prog Urol 2009; 19: 112-5. https://doi.org/10.1016/j.purol.2008.10.008

Ammani A, Janane A, Chafiki J. Profil épidémiologique du cancer de la prostate dans le service d’urologie de l’hôpital Mohammed V de Rabat. J Maroc Urol 2007; 5: 11-4.

Soulié M, Villiers A, Grosclaude P, Menegos F, Schaffer P, Mace-Lesec'h J, et al. Le cancer de la prostate en France: résultats de l’enquête CCAFU-FRANCIM. Prog Urol 2001; 11: 478-85.

Diallo AB, Youwe Dombeu N, Barry AM. Caractéristiques cliniques du cancer de la prostate en Guinée. Résultats sur la période 2000-2006. African J Urol 2007; 13(4): 280-7.

Bo M, Ventura M, Marinello R, Capello S, Casetta G, Fabris F. Relationship between prostatic specific antigen (PSA) and volume of the prostate in the benign hyperplasia in the elderly. Crit Rev Oncol Hematol 2007; 47: 207-11. https://doi.org/10.1016/S1040-8428(03)00094-5

Roherborn CG, Boyle P, Gould L, Waldstreicher J. Serum prostate specific antigen as predictor of prostate volume in men with benign prostate hyperplasia. Urol 1998; 53: 581-9. https://doi.org/10.1016/S0090-4295(98)00655-4

Hammerer PG, McNeal JE, Stamey TA. Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate. J urol 1995; 153: 111-4. https://doi.org/10.1097/00005392-199501000-00038

Rietbergen JBW, Kranse R, Hoedemaeker RF, Boeken Kruger AE, Bangma CH, Kirkels WJ, et al. Comparison of prostate-specific antigen corrected for total prostate volume and transition zone volume in a population-based screening study. Urology 1998; 52: 237-46. https://doi.org/10.1016/S0090-4295(98)00138-1

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127(12): 2893-917. https://doi.org/10.1002/ijc.25516

Fournier G, Valeri A, Mangin P, Cussenot O. Cancer de la prostate. Epidémiologie. Facteurs de risques. Anatomopathologie. Annales d’urologie 2004; 38: 187-06. https://doi.org/10.1016/j.anuro.2004.07.001

Smith JR, Freije D, Carpten JD, Grönberg H, Xu J, Isaacs SD, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996; 274: 1371-74. https://doi.org/10.1126/science.274.5291.1371

Toubert ME, Schlageter MH, Bron I. Dépistage du cancer de la prostate. Presse Médicale, Paris, Masson 2003; 24(12): 1139-42.

• PDF